Cara Therapeutics, Inc. (NASDAQ:CARA) Shares Bought by Texas Permanent School Fund

Texas Permanent School Fund raised its position in Cara Therapeutics, Inc. (NASDAQ:CARAGet Rating) by 6.3% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 32,232 shares of the biopharmaceutical company’s stock after acquiring an additional 1,918 shares during the quarter. Texas Permanent School Fund’s holdings in Cara Therapeutics were worth $302,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of CARA. KBC Group NV acquired a new stake in Cara Therapeutics in the 2nd quarter worth about $36,000. Mutual of America Capital Management LLC boosted its holdings in shares of Cara Therapeutics by 17.9% during the 2nd quarter. Mutual of America Capital Management LLC now owns 7,111 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 1,078 shares during the last quarter. Federated Hermes Inc. boosted its holdings in shares of Cara Therapeutics by 27.7% during the 1st quarter. Federated Hermes Inc. now owns 6,009 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 1,302 shares during the last quarter. Cetera Advisor Networks LLC acquired a new position in shares of Cara Therapeutics during the 2nd quarter worth approximately $93,000. Finally, Rafferty Asset Management LLC acquired a new position in shares of Cara Therapeutics during the 2nd quarter worth approximately $97,000. 69.26% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CARA shares. StockNews.com started coverage on Cara Therapeutics in a report on Wednesday, October 12th. They set a “hold” rating on the stock. Piper Sandler lowered their target price on Cara Therapeutics to $25.00 in a report on Tuesday, November 15th. One analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.60.

Cara Therapeutics Stock Performance

CARA stock opened at $10.85 on Tuesday. The firm has a market cap of $583.01 million, a PE ratio of -6.54 and a beta of 1.00. The firm’s 50 day moving average price is $11.05 and its 200-day moving average price is $10.33. Cara Therapeutics, Inc. has a one year low of $7.40 and a one year high of $13.97.

Cara Therapeutics (NASDAQ:CARAGet Rating) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.01). The firm had revenue of $10.81 million during the quarter, compared to analysts’ expectations of $8.39 million. Cara Therapeutics had a negative net margin of 224.51% and a negative return on equity of 43.13%. Equities research analysts predict that Cara Therapeutics, Inc. will post -1.31 EPS for the current fiscal year.

Insider Buying and Selling at Cara Therapeutics

In other Cara Therapeutics news, CEO Christopher Posner sold 14,470 shares of the business’s stock in a transaction that occurred on Wednesday, November 16th. The stock was sold at an average price of $11.13, for a total value of $161,051.10. Following the sale, the chief executive officer now owns 186,561 shares of the company’s stock, valued at $2,076,423.93. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Cara Therapeutics news, insider Joana Goncalves sold 2,992 shares of the business’s stock in a transaction that occurred on Wednesday, December 21st. The stock was sold at an average price of $11.27, for a total value of $33,719.84. Following the sale, the insider now owns 71,901 shares of the company’s stock, valued at $810,324.27. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Christopher Posner sold 14,470 shares of the business’s stock in a transaction on Wednesday, November 16th. The stock was sold at an average price of $11.13, for a total transaction of $161,051.10. Following the completion of the transaction, the chief executive officer now owns 186,561 shares of the company’s stock, valued at approximately $2,076,423.93. The disclosure for this sale can be found here. Insiders have sold a total of 20,968 shares of company stock valued at $234,284 over the last quarter. 3.20% of the stock is owned by company insiders.

Cara Therapeutics Company Profile

(Get Rating)

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

See Also

Want to see what other hedge funds are holding CARA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cara Therapeutics, Inc. (NASDAQ:CARAGet Rating).

Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.